November 2, 2021

Dear CMT Community,

As you may have seen, the Charcot-Marie Tooth Association (CMTA) recently announced a venture philanthropy grant to Taysha Gene Therapies for sponsoring a Charcot-Marie Tooth (CMT) disease type 4A (CMT4A) gene therapy study. It is our pleasure to introduce the CMT community to Taysha Gene Therapies. In a short amount of time, Taysha has built an experienced team with deep roots in gene therapy research and development and an unrelenting patient-centric focus. We were founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern), a gene therapy incubator, and together we have constructed a robust engine to discover and develop new treatments for CNS disease.

Taysha and the CMTA will jointly fund the study at UT Southwestern under the direction of Xin Chen, Ph.D. and Steven Gray, Ph.D., co-principal investigators. The findings from this study will be critical in advancing research that will potentially lead to clinical trials for CMT4A patients.

“\textit{I am proud to be a part of the CMT4A community. Having worked in gene therapy and rare diseases for many years now, I know how critical it is to partner with others to bring gene therapies to individuals impacted by this disease.}”

– R.A. Session II, President, Founder & CEO

Taysha is headquartered in Dallas, Texas, and in the Caddo Native American language, Taysha means “ally” or “friend.” When translated, it also means “Texas.” Between our UT Southwestern collaboration and patient advocacy partnerships, we hope to be an ally to the CMT community. You can learn more about our commitment to being an ally in rare disease by visiting \url{https://tayshagtx.com/rare-ally/}.

We are encouraged by the strength of the CMT patient community and our shared goal of advancing gene therapy efforts for individuals impacted by this condition. We look forward to our collaboration and commit to providing you with updates as we have more information available.

Warm regards,

The Taysha Team

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely, including those described in our filings with the Securities and Exchange Commission, which is available at \url{www.sec.gov}. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

© Taysha Gene Therapies 2021. All rights reserved TSHA-CMT-0036-2021